WHO Warns About the Use of Remdesivir in COVID-19 Patients, Has Little or No Effect
WHO has issued a conditional recommendation against the use of remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.
This recommendation, released on 20 November, is part of a living guideline on clinical care for COVID-19. It was developed by an international guideline development group, which includes 28 clinical care experts, 4 patient-partners and one ethicist.
The guidelines were developed in collaboration with the non-profit Magic Evidence Ecosystem Foundation (MAGIC), which provided methodologic support. The guidelines are an innovation, matching scientific standards with the speed required to respond to an ongoing pandemic.
Work on this began on 15 October when the WHO Solidarity Trial published its interim results. Data reviewed by the panel included results from this trial, as well as 3 other randomized controlled trials. In all, data from over 7000 patients across the 4 trials were considered.
The evidence suggested no important effect on mortality, need for mechanical ventilation, time to clinical improvement, and other patient-important outcomes.
The guideline development group recognized that more research is needed, especially to provide higher certainty of evidence for specific groups of patients. They supported continued enrollment in trials evaluating remdesivir.
We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!
- » Over 10,000 Active Cases of COVID-19 in Bulgaria
- » Study: High Caffeine Consumption - Higher Risk of Blinding Eye Disease
- » Covild-19: Indian Variant Found In Bulgaria Likely to Remain Isolated Case
- » COVID-19 in Bulgaria: 110 New Cases
- » UU Health Commissioner Meets with Bulgarian Caretaker Minister of Health, Talks EU Covid Certificate
- » First Case of Indian Coronavirus Variant Detected in Bulgaria